Monday watchlist, March 30: Track Sun Pharma, HDFC Bank and ICICI as market volatility surges; review key stock setups and…
India ramps up enforcement against unauthorised sale and promotion of GLP-1 weight-loss drugs after generics hit the market, with inspections…
An endurance question turned into a consumer nutrition business, Built through failed trials, a stalled export, and a restart in…
Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and Glenmark have…
Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7…
A key US drug approval is putting this pharma stock back on the radar, with a global brokerage pointing to…
Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!
This article explores the burgeoning intersection of India’s trade momentum and the logistics sector. With cumulative exports reaching $720.8 billion…
While Nifty Pharma giants struggle with regulatory headwinds and pricing pressures, two outliers are quietly catching the attention of smart…
Markets watchlist today, March 09: Nifty faces bearish pressure this March; watch HDFC Bank, SBI, Tata Steel, and Vedanta for…
India’s pharmaceutical industry could face losses of Rs 2,500–5,000 crore as Middle East tensions disrupt shipping routes and double freight…
Rajji Mehdwan, Managing Director and CEO of Roche India & Neighbouring Markets, said that Emcure’s robust distribution network and clinical…
With the war expanding to other countries, exporters are still awaiting updates on their cargoes at sea. They say it…
Department of Commerce data shows that India exported pharma products worth $911.9 million in 10 West Asian countries in FY25…
Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen device to improve affordability…
Novartis AG to sell its entire 70.68% stake in Novartis India for Rs 1,445.89 crore. Buyers including WaveRise Investments and…
Monthly treatment costs for popular weight-loss drugs like Ozempic and Wegovy are expected to plummet from ₹12,000 to nearly ₹3,000…
Pharma giant USV has finalized an all-cash acquisition of a 79% stake in Wellbeing Nutrition, valuing the D2C startup at…